ANO10 mutational screening in recessive ataxia: genetic findings and refinement of the clinical phenotype.
ARCA3
Dysexecutive cognitive syndrome
SCAR10, recessive ataxia
Somatosensory evoked potentials
Spastic ataxia
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
14
08
2018
accepted:
24
11
2018
revised:
22
11
2018
pubmed:
6
12
2018
medline:
29
5
2019
entrez:
6
12
2018
Statut:
ppublish
Résumé
Autosomal recessive cerebellar ataxia type 3 (ARCA3) is a rare inherited disorder caused by mutations in the ANO10 gene. The disease is characterized by slowly progressive spastic ataxia variably associated with motor neuron involvement, epilepsy, and cognitive decline. We performed mutational screening in 80 patients with sporadic or autosomal recessive adult-onset ataxia. We identified 11 ANO10 gene variants in 10 patients from 8 families (10%): 4 mutations were previously described and 7 were novel. Age at onset ranged between 27 and 53 years. All patients presented ataxia, pyramidal signs and cerebellar atrophy at brain MRI. Additional signs were bradykinesia (7/10), mild vertical gaze paresis (5/10), pes cavus (4/10), and sphincteric disturbances (3/10). Six patients, with normal MMSE score, failed several neuropsychological tests rating executive functions. Three patients had giant somatosensory evoked potentials and epileptic spikes in EEG without clinical evidence of seizures. Our observational study indicates a high frequency of ARCA3 disease in sporadic patients with adult-onset cerebellar ataxia. We extended the ANO10 mutational spectrum with the identification of novel gene variants, and further defined the clinical, cognitive, and neurophysiological features in a new cohort of patients. These findings may contribute to the refinement of the complex ARCA3 phenotype and be valuable in clinical management and natural history studies.
Identifiants
pubmed: 30515630
doi: 10.1007/s00415-018-9141-z
pii: 10.1007/s00415-018-9141-z
doi:
Substances chimiques
ANO10 protein, human
0
Anoctamins
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
378-385Subventions
Organisme : Ministero della Salute
ID : RF-2011-02351165
Organisme : Ministero della Salute
ID : RF-2011-02347420
Références
Clin Neurophysiol. 2001 May;112(5):793-9
pubmed: 11336894
Acta Neurol Scand. 2002 Oct;106(4):209-12
pubmed: 12225316
Clin Neurophysiol. 2003 Jun;114(6):1041-52
pubmed: 12804673
Am J Hum Genet. 2010 Dec 10;87(6):813-9
pubmed: 21092923
J Neurol. 2012 May;259(5):906-11
pubmed: 22008874
Clin Neurophysiol. 2013 May;124(5):1013-8
pubmed: 23276489
Clin Genet. 2014 Mar;85(3):296-7
pubmed: 23551081
JAMA Neurol. 2014 Oct;71(10):1305-10
pubmed: 25089919
JAMA Neurol. 2014 Oct;71(10):1237-46
pubmed: 25133958
J Neurol. 2014 Nov;261(11):2192-8
pubmed: 25182700
J Hum Genet. 2014 Oct;59(10):589-90
pubmed: 25209172
JAMA Neurol. 2015 Feb;72(2):238-9
pubmed: 25664549
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Eur Neurol. 2016;75(3-4):186-90
pubmed: 27045840
Brain. 2016 May;139(Pt 5):1378-93
pubmed: 27086870
J Clin Neurophysiol. 2017 Jan;34(1):84-91
pubmed: 27490324
Mov Disord. 2016 Dec;31(12):1929-1931
pubmed: 27787937
Cerebellum Ataxias. 2017 Feb 23;4:3
pubmed: 28250961
Front Neurol. 2017 Mar 03;8:71
pubmed: 28316589
J Neuropsychol. 2018 Sep;12(3):471-483
pubmed: 28477351
JAMA Neurol. 2018 May 1;75(5):591-599
pubmed: 29482223
Neurology. 2018 May 1;90(18):e1578-e1587
pubmed: 29602913
Curr Opin Neurol. 2018 Aug;31(4):462-471
pubmed: 29847346
Genet Med. 2019 Jan;21(1):195-206
pubmed: 29915382
Cerebellum. 2019 Feb;18(1):33-46
pubmed: 29949096
Prog Biophys Mol Biol. 1995;64(2-3):237-78
pubmed: 8987386
Brain. 1998 Apr;121 ( Pt 4):561-79
pubmed: 9577385